Table 1.
Baseline Characteristics (n=33)
| Demographics | |
| Age (years) | 74 [70–81] |
| Male sex | 11 (33) |
| Ischemic etiology | 8 (24) |
| Body weight (kg) | 55.0 [49.0–66.0] |
| BMI (kg/m2) | 22.4 [19.8–25.7] |
| BSA (m2) | 1.59 [1.42–1.70] |
| NYHA functional class | |
| Class II | 21 (64) |
| Class III | 12 (36) |
| Class IV | 0 |
| Comorbidity | |
| Atrial fibrillation | 16 (49) |
| Diabetes | 9 (27) |
| Hypertension | 33 (100) |
| History of HF hospitalization | 7 (21) |
| Hemodynamics | |
| SBP (mmHg) | 135 [123–148] |
| DBP (mmHg) | 76 [71–84] |
| Heart rate (beats/min) | 75 [65–89] |
| Laboratory data | |
| Serum potassium (mEq/L) | 4.2 [3.9–4.5] |
| eGFR (mL/min/1.73 m2) | 52.9 [42.8–62.1] |
| Plasma BNP (pg/mL) | 164 [100–312] |
| Echocardiography | |
| LVEDd (mm) | 51 [45–54] |
| LVEF (%) | 55 [50–63] |
| Left atrial diameter (mm) | 40 [37–51] |
| LVMI (g/m2) | 148.5 [126.3–186.6] |
| Medication | |
| β-blocker | 28 (85) |
| RAS inhibitor | 27 (82) |
| Calcium channel blocker | 11 (33) |
| Diuretic | 27 (82) |
Continuous variables are presented as the median [interquartile range]; categorical variables are presented as n (%). BMI, body mass index; BNP, B-type natriuretic peptide; BSA, body surface area; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration ratio; HF, heart failure; LVEDd, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; NYHA, New York Heart Association; RAS, renin-angiotensin system; SBP, systolic blood pressure.